Overview
Methylcobalamin deficiency type cblDv1 is an extremely rare inherited metabolic disorder that affects how the body processes vitamin B12 (cobalamin). Specifically, it disrupts the production of methylcobalamin, one of the two active forms of vitamin B12 that the body needs. This active form is essential for an enzyme called methionine synthase, which plays a key role in converting the amino acid homocysteine into methionine. When this process does not work properly, homocysteine builds up in the blood and urine (a condition called homocystinuria), while methionine levels become abnormally low. The disease is caused by mutations in the MMADHC gene. In the cblDv1 variant, only the methylcobalamin pathway is affected, while the other cobalamin pathway (adenosylcobalamin production) remains intact. This distinguishes it from other cblD subtypes that may affect both pathways or only the adenosylcobalamin pathway. Symptoms typically appear in infancy or early childhood and can include developmental delays, feeding difficulties, megaloblastic anemia (a type of anemia where red blood cells are abnormally large), neurological problems such as seizures and low muscle tone, and failure to thrive. Without treatment, the condition can lead to significant intellectual disability and progressive neurological damage. Treatment generally involves supplementation with hydroxocobalamin (a form of vitamin B12) and betaine to help lower homocysteine levels. Early diagnosis and prompt treatment are critical to improving outcomes, though the long-term prognosis can vary depending on how early treatment begins and how well the body responds.
Also known as:
Key symptoms:
Developmental delayMegaloblastic anemia (large, abnormal red blood cells)Low muscle tone (floppy baby)SeizuresFeeding difficultiesFailure to thrive or poor weight gainIntellectual disabilityElevated homocysteine in blood and urineLow methionine levels in bloodLethargy or excessive sleepinessPoor growthBehavioral changesWalking or movement difficulties
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for Methylcobalamin deficiency type cblDv1.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Methylcobalamin deficiency type cblDv1 at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Methylcobalamin deficiency type cblDv1.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Methylcobalamin deficiency type cblDv1.
Community
No community posts yet. Be the first to share your experience with Methylcobalamin deficiency type cblDv1.
Start the conversation →Latest news about Methylcobalamin deficiency type cblDv1
No recent news articles for Methylcobalamin deficiency type cblDv1.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.How severe is my child's condition based on the specific genetic mutations found?,What is the recommended treatment plan, and how often will injections be needed?,How frequently should blood tests be done to monitor homocysteine and methionine levels?,What developmental therapies should we start, and how soon?,Are there any signs or symptoms I should watch for that would require emergency care?,What is the expected long-term outlook for my child with treatment?,Should other family members be tested for carrier status, and what are the implications for future pregnancies?
Common questions about Methylcobalamin deficiency type cblDv1
What is Methylcobalamin deficiency type cblDv1?
Methylcobalamin deficiency type cblDv1 is an extremely rare inherited metabolic disorder that affects how the body processes vitamin B12 (cobalamin). Specifically, it disrupts the production of methylcobalamin, one of the two active forms of vitamin B12 that the body needs. This active form is essential for an enzyme called methionine synthase, which plays a key role in converting the amino acid homocysteine into methionine. When this process does not work properly, homocysteine builds up in the blood and urine (a condition called homocystinuria), while methionine levels become abnormally low.
How is Methylcobalamin deficiency type cblDv1 inherited?
Methylcobalamin deficiency type cblDv1 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Methylcobalamin deficiency type cblDv1 typically begin?
Typical onset of Methylcobalamin deficiency type cblDv1 is infantile. Age of onset can vary across affected individuals.